ES8800157A1 - Un procedimiento para preparar derivados de tironina - Google Patents

Un procedimiento para preparar derivados de tironina

Info

Publication number
ES8800157A1
ES8800157A1 ES551005A ES551005A ES8800157A1 ES 8800157 A1 ES8800157 A1 ES 8800157A1 ES 551005 A ES551005 A ES 551005A ES 551005 A ES551005 A ES 551005A ES 8800157 A1 ES8800157 A1 ES 8800157A1
Authority
ES
Spain
Prior art keywords
raised
formula
hydroxy
compound
chemical compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES551005A
Other languages
English (en)
Other versions
ES551005A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of ES8800157A1 publication Critical patent/ES8800157A1/es
Publication of ES551005A0 publication Critical patent/ES551005A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR DERIVADOS DE TIRONINA. CONSISTE EN HACER REACCIONAR UN COMPUESTO DE FORMULA (II) CON UN COMPUESTO DE FORMULA (III) EN CLOROFORMO, EN PRESENCIA DE TRIATILAMINA Y SALES DE COBRE, PARA OBTENER UN COMPUESTO DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SIENDO: (A-), ANION TRIS-TRIFLUOROACETATO; AR Y AR'', 4-HIDROXIFENILO O 5-HIDROXI-2-PIRIDILO; G ELEVADO A 1, CHOCN Y CH2HAL; G ELEVADO A 2, HIDROXI FENOLICO PROTEGIDO; R ELEVADO A 1, -CH2CR ELEVADO A 2 R ELEVADO A 3 NR ELEVADO A 4 R ELEVADO A 5 O YCOR ELEVADO A 6; R ELEVADO A 2, R ELEVADO A 4 Y R ELEVADO A 10, H O ALQUILO DE C1 A 4; R ELEVADO A 3, H O -COR ELEVADO A 6, R ELEVADO A 5, H, ALQUILO DE C 1 A 4; R ELEVADO A 6, HIDROXI, ALCOXI DE C 1 A 4 Y OTROS; R ELEVADO A 7 Y R ELEVADO A 8, H, HAL O AMONIO; R ELEVADO A 9, HIDROXI; X, O O S; E Y, ALQUILENO DE C 1 A 4. SE UTILIZAN PARA COMBATIR LA DEFICIENCIA DE LA TIROIDES EN SERES HUMANOS. *FORMULA*
ES551005A 1985-01-18 1986-01-17 Un procedimiento para preparar derivados de tironina Expired ES8800157A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858501372A GB8501372D0 (en) 1985-01-18 1985-01-18 Chemical compounds

Publications (2)

Publication Number Publication Date
ES8800157A1 true ES8800157A1 (es) 1987-11-01
ES551005A0 ES551005A0 (es) 1987-11-01

Family

ID=10573093

Family Applications (1)

Application Number Title Priority Date Filing Date
ES551005A Expired ES8800157A1 (es) 1985-01-18 1986-01-17 Un procedimiento para preparar derivados de tironina

Country Status (24)

Country Link
US (3) US4766121A (es)
EP (1) EP0188351B1 (es)
JP (1) JPH07103070B2 (es)
KR (1) KR930011302B1 (es)
CN (1) CN1010310B (es)
AT (1) ATE61581T1 (es)
AU (1) AU577917B2 (es)
CA (1) CA1319148C (es)
DE (1) DE3678000D1 (es)
DK (1) DK164592C (es)
ES (1) ES8800157A1 (es)
FI (1) FI860229A7 (es)
GB (1) GB8501372D0 (es)
GR (1) GR860122B (es)
HU (1) HU194807B (es)
IE (1) IE58867B1 (es)
IL (1) IL77605A (es)
JO (1) JO1439B1 (es)
NO (1) NO860159L (es)
NZ (1) NZ214843A (es)
PH (1) PH22691A (es)
PT (1) PT81844B (es)
ZA (1) ZA86319B (es)
ZW (1) ZW886A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5371284A (en) * 1987-09-03 1994-12-06 Schering Corporation Phenyl acetylenic acetals
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DE69314718T2 (de) * 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6236946B1 (en) 1995-12-13 2001-05-22 Thomas S. Scanlan Nuclear receptor ligands and ligand binding domains
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
HK1044532A1 (zh) 1999-03-01 2002-10-25 辉瑞产品公司 用作甲状腺受体配体的草氨酸及衍生物
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6627660B1 (en) * 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
WO2001070687A1 (de) * 2000-03-23 2001-09-27 Bayer Aktiengesellschaft Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können
DZ3276A1 (fr) * 2000-03-31 2001-10-04 Pfizer Prod Inc Acides malonamiques et leurs derives, utiles comme ligands de recepteurs thyroidiens
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
DE10024939A1 (de) * 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
EP1347959A1 (de) 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
EP1499578A2 (en) 2001-08-24 2005-01-26 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
GB0120691D0 (en) * 2001-08-24 2001-10-17 Karobio Ab Novel Compounds
ATE313325T1 (de) 2001-09-26 2006-01-15 Pfizer Prod Inc Indolcaroboxylsäure als thyroidrezeptor-liganden
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
JP4810862B2 (ja) * 2005-04-11 2011-11-09 Ｊｓｒ株式会社 オニウム塩、それを用いた感放射線性酸発生剤及びポジ型感放射線性樹脂組成物
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
WO2007002036A1 (en) * 2005-06-24 2007-01-04 Thomas Lavin Tyroid hormone in burn and adipose deposites
DK1919878T3 (da) 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
EP2066800A2 (en) * 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR289M (fr) * 1959-01-05 1961-02-24 Glaxo Lab Ltd Médicament utilisable dans le traitement de l'hypercholestérolémie et des états apparentés, a base de dérivés de la thyronine.
US3017428A (en) * 1959-08-18 1962-01-16 Univ California Antihypercholesterolemic thyronine derivatives
US3149153A (en) * 1961-12-05 1964-09-15 Smith Kline French Lab 3'-substituted-3, 5-diiodothyronine and salts thereof
DE1200832B (de) * 1961-12-05 1965-09-16 Smith Kline French Lab Verfahren zur Herstellung von 3, 5-Dijodthyroninderivaten
US3287396A (en) * 1963-01-11 1966-11-22 Smith Kline French Lab Phenyldesoxythyronines
GB1047082A (en) * 1963-02-01 1966-11-02 Pfizer & Co C Thyronine derivatives
US3477954A (en) * 1966-06-29 1969-11-11 Armour Pharma Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds

Also Published As

Publication number Publication date
IL77605A0 (en) 1986-07-31
GB8501372D0 (en) 1985-02-20
FI860229A7 (fi) 1986-07-19
EP0188351A2 (en) 1986-07-23
PH22691A (en) 1988-11-14
NO860159L (no) 1986-07-21
US4826876A (en) 1989-05-02
AU577917B2 (en) 1988-10-06
EP0188351A3 (en) 1989-03-15
FI860229A0 (fi) 1986-01-17
DK18586D0 (da) 1986-01-15
JPS61167643A (ja) 1986-07-29
PT81844B (pt) 1988-05-27
US4766121A (en) 1988-08-23
NZ214843A (en) 1989-02-24
ATE61581T1 (de) 1991-03-15
CN86100894A (zh) 1986-09-03
KR930011302B1 (ko) 1993-11-29
DK18586A (da) 1986-07-19
HUT40401A (en) 1986-12-28
KR860005788A (ko) 1986-08-13
ZA86319B (en) 1986-08-27
DK164592B (da) 1992-07-20
HU194807B (en) 1988-03-28
CA1319148C (en) 1993-06-15
DE3678000D1 (de) 1991-04-18
IE58867B1 (en) 1993-11-17
IL77605A (en) 1990-02-09
AU5221986A (en) 1986-07-24
US4910305A (en) 1990-03-20
JO1439B1 (en) 1988-03-10
JPH07103070B2 (ja) 1995-11-08
CN1010310B (zh) 1990-11-07
ZW886A1 (en) 1987-05-13
GR860122B (en) 1986-05-19
ES551005A0 (es) 1987-11-01
DK164592C (da) 1992-12-07
IE860143L (en) 1986-07-18
EP0188351B1 (en) 1991-03-13
PT81844A (en) 1986-02-01

Similar Documents

Publication Publication Date Title
ES8800157A1 (es) Un procedimiento para preparar derivados de tironina
LU88670I2 (fr) Fluvastatine eventuellement sous forme de sel par exemple sel de sodium
ES8705400A1 (es) Un procedimiento para la preparacion de nuevos derivados de fenoxialquilaminopirimidina.
IL148516A (en) Retroviral protease inhibiting compound
FI891176A0 (fi) Peptidfoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
EP0236140A3 (en) Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
ES2021266B3 (es) Nuevos derivados de quinazolina, procedimiento para su produccion y composiciones farmaceuticas que los contienen.
JPS6425777A (en) Organic salt of physostigmine
DK232989D0 (da) Antiviralt praeparat
ATE50559T1 (de) Substituierte p,p'-methylen-bis-aniline.
FI892675L (fi) 2,6-dihalogenpyridin-3 -karboxylsyraderivat och deras framstaellning.
MY102081A (en) 1,3-oxazolidine-2-one derivatives and processes for their preparation
EG15762A (en) Substituted hydroxy-malonic acid diamides,a process for their preparation,and their use as pest combating agents
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
ES2182086T3 (es) Nuevos derivados de peptidil-arginina aldehido.
ES8504774A1 (es) Procedimiento para preparar derivados de 2-piperacinil-quinazolina
KR840006238A (ko) 신규 α-아릴-α-피리딜알카노인산 유도체의 제조방법
EP0210642A3 (en) Surfactants derived from succinic acid
TNSN89109A1 (fr) Procede de preparation de nouveaux derives de la methoxycarbonyl-2 n,n'-di (trimethoxybenzoyle) piperazine
AU569033B2 (en) (+)-cyanidan-3-ol derivatives
JPS548627A (en) 2-alkoxyalkoxy-5-nitrobenzenesulfonic acid and its salt
ES8306479A1 (es) "procedimiento de obtencion de 2-amino-4-hidroxi-5-halogenopirimidinas".
DE3464598D1 (en) Acetylene derivatives having an enzyme-inhibiting activity, their preparation and their use as medicines
TH3059A (th) เบต้า-แนพธิลอัลคิลอะมีน
EP0196126A3 (en) Herbicidal substituted triazine compounds

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070903